ClinicalTrials.gov
ClinicalTrials.gov Menu

Queen's University Investigation of Calcification in Chronic Kidney Disease (QUICK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00687661
Recruitment Status : Completed
First Posted : June 2, 2008
Last Update Posted : September 28, 2015
Sponsor:
Information provided by (Responsible Party):
Dr. Karen Yeates, Queen's University

Brief Summary:

Kidney disease is a fundamental part of medicine because of its prominence in Western society. Common conditions such as diabetes, hypertension and kidney infections can all progress to End-Stage Renal Disease (ESRD) also known as Stage 5 chronic kidney disease (CKD 5). Once ESRD has begun, kidney function is poor at best, thus the body is unable to effectively clear harmful toxins from the blood.

A common feature of ESRD is vascular calcification, a process where blood vessels (especially arteries) attract deposits of the mineral calcium. Over time, these deposits harden and thicken in the layers of blood vessels, which limit blood flow to body tissues and can produce significant disease including hypertension, heart disease and stroke. Although the process of vascular calcification is unknown, there is mounting evidence that it is mediated by cellular events that are similar to those seen in bone formation with in the body (osteogenesis). With this point in mind, it has been suggested that agents medicine employs to limit excess bone formation will reduce the rate of vascular calcification in CKD Stage 5.

This study will employ one group of drugs called bisphosphonates which have been used to limit bone formation. It will study their effect on vascular calcification in adult dialysis patients.


Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Drug: Bisphosphonate Drug: Placebo Phase 3

Detailed Description:

Presently, there exist few therapies aimed at retarding the progression of vascular calcification. One study showed that agents that limit the absorption of phosphate from food (phosphate binders) slow the progression of vascular calcification, and as a result, treatments emphasize phosphate control through diet and phosphate binders. Other studies have shown that the use of statins, to lower LDL cholesterol levels may reduce the progression of coronary calcification in non-ESRD patients, but data from ESRD are lacking. While these treatments have been helpful, the improvements in patients' outcomes have not been overwhelming positive.

This proposed study is not the first to study the use of bisphosphonates on vascular calcification. Repeated studies have shown impressive reduction in calcification rates in several animal models, which begs the question, how will bisphosphonates fare in human subjects? Preliminary research has begun, but clearly an expansive trial on humans is needed to explore the use of a promising therapy. Our study hopes to provide insight into this area of cardiovascular research.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: The Use of Bisphosphonates to Prevent or Delay the Progression of Vascular Calcification in End-Stage Renal Disease: A Randomized Controlled Trial
Study Start Date : October 2008
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1
Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
Drug: Bisphosphonate
35mg given orally once weekly for 24 months
Other Name: Residronate
Placebo Comparator: 2
Arm #2 will include patients randomized to receive placebo therapy for 24 months
Drug: Placebo
identical placebo pill once weekly for 24 months



Primary Outcome Measures :
  1. Absolute change in coronary artery calcification score (CaSc) from baseline to study completion. [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Change in bone density score (wrist/hip) as calculated by Ct scanning method, # fractures, MI, Stroke, amputation/surgery for peripheral revascularization. [ Time Frame: 24 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age
  • receiving maintenance renal replacement therapy for less than 12 months
  • incident patients starting renal replacement therapy for the first time

Exclusion Criteria:

  • active vasculitis
  • severe hypocalcemia
  • previous adverse side effect to bisphosphonate use
  • current use of corticosteroids
  • weight greater than 300 pounds
  • pregnancy
  • not expected to survive greater than one year
  • expected to discontinue renal replacement therapy during the study period or recover renal function
  • evidence of adynamic bone disease
  • current bisphosphonate use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00687661


Locations
Canada, Ontario
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Sponsors and Collaborators
Queen's University
Investigators
Principal Investigator: Karen E Yeates, Dr Queen's University

Responsible Party: Dr. Karen Yeates, Dr Karen E. Yeates, Department of Medicine Queen's University., Queen's University
ClinicalTrials.gov Identifier: NCT00687661     History of Changes
Other Study ID Numbers: QUICK Study
J.P.Bickell Foundation Grant
8 April 2005
First Posted: June 2, 2008    Key Record Dates
Last Update Posted: September 28, 2015
Last Verified: September 2015

Keywords provided by Dr. Karen Yeates, Queen's University:
Chronic Kidney Failure
Vascular Calcification
Bisphosphonates

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Calcinosis
Vascular Calcification
Urologic Diseases
Renal Insufficiency
Calcium Metabolism Disorders
Metabolic Diseases
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs